- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00819013
Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults (FLU-A)
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Reactogenicity, and Immunogenicity of Recombinant M2e Influenza-A Vaccine Candidate ACAM FLU-A) in Healthy Adults
This multi-center study will be conducted in the United States with up to 80 healthy adult subjects. Subjects will be scheduled to receive a total of two (2) injections with 1 injection each administered.
Subjects will be randomized according to a randomization scheme.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33143
- Miami Research Associates
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- Johnson County Clin-Trials
-
-
Washington
-
Tacoma, Washington, United States, 98418
- Northwest Kinetics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult males or females 18 - 40 years of age in good general health
Exclusion Criteria:
- Known allergies or severe reactions to any of the vaccine components including those to adjuvants
- History of severe allergic reactions, including angioedema;
- History of asthma or recurrent wheezing; (current or within past 2 years);
- History of neurological symptoms or signs following administration of any vaccine;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study Group 1
ACAM-FLU-A low dose + Adjuvant 1
|
0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
Other Names:
0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
Other Names:
0.5 mL ACAM FLU-A low dose, Intramuscular
Other Names:
|
Experimental: Study Group 2
ACAM-FLU-A low dose + Adjuvant 2
|
0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
Other Names:
0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
Other Names:
0.5 mL ACAM FLU-A low dose, Intramuscular
Other Names:
|
Experimental: Study Group 3
ACAM-FLU-A low dose
|
0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
Other Names:
0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
Other Names:
0.5 mL ACAM FLU-A low dose, Intramuscular
Other Names:
|
Placebo Comparator: Study Group 4
Saline placebo
|
0.5 mL, Intramuscular
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Reporting Adverse Events by System Organ Class After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or a Placebo Vaccine.
Time Frame: Day 0 through Day 60 post-vaccination
|
Day 0 through Day 60 post-vaccination
|
|
Number of Participants Reporting a Solicited Injection Site or Systemic Adverse Event After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.
Time Frame: Day 0 through Day 7 post-vaccination
|
Solicited Injection Site Adverse Events: Erythema, Induration, Pain, Pruritus, Swelling, Rash.
Solicited Systemic Adverse Events: Lymph Node Pain, Pyrexia (Temperature), Chills, Constipation, Diarrhoea, Fatigue, Headache, Malaise, Myalgia, Nausea, Vomiting, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Creatinine Increased, Haemoglobin Decreased, Platelet Count Decreased, White Blood Cell Count Increased.
|
Day 0 through Day 7 post-vaccination
|
Number of Participants With Evaluated Laboratory Abnormalities After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.
Time Frame: Day 0 through Day 60 post-vaccination 1
|
Day 0 through Day 60 post-vaccination 1
|
|
Number of Participants With Seroconversion to M2e Antigen During Initial Treatment and Follow Up Period After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine
Time Frame: Day 15 through Month 10 Post-vaccination 1
|
Seroconversion was defined as an end point anti M2e antibody titer ≥ 100.
Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA)
|
Day 15 through Month 10 Post-vaccination 1
|
Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or a Placebo Vaccine.
Time Frame: Day 15 through Month 10 Post-vaccination 1
|
Antibody responses to the respective vaccines were assessed by means of enzyme linked immunosorbent assay (ELISA). A GMT value of 50.0 indicates a titer at or below the lowest limit of quantitation (LLOQ) |
Day 15 through Month 10 Post-vaccination 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Signs and Symptoms of Influenza After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.
Time Frame: Month 4 through Month 10 post-vaccination 1
|
Participants who reported signs and symptoms of influenza were tested using nasal pharyngeal swabs, with secretions cultured using susceptible tissue culture cell lines.
Positive cultures were confirmed as influenza using immunofluorescence techniques with influenza strain specific antibodies.
|
Month 4 through Month 10 post-vaccination 1
|
Number of Participants With Seroconversion to M2e Antigen by Immunoglobulin G (IgG) Subclasses Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.
Time Frame: Day 0 and Day 60 Post-vaccination 1
|
Seroconversion was defined as an antibody Titer ≥ 100.
Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA)
|
Day 0 and Day 60 Post-vaccination 1
|
Geometric Mean Titers of Anti-M2e Antigen by Immunoglobulin G (IgG) Subclasses Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.
Time Frame: Day 0 and Day 60 Post-vaccination 1
|
Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA). A GMT value of 50.0 indicates a titer at or below the lowest limit of quantitation (LLOQ). |
Day 0 and Day 60 Post-vaccination 1
|
Geometric Mean Titer Ratios of Anti-M2e Antigen by Immunoglobulin G (IgG) Subclasses Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.
Time Frame: Day 0 and Day 60 Post-vaccination 1
|
Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA).
|
Day 0 and Day 60 Post-vaccination 1
|
Geometric Mean Titers (GMTs) of Anti-Hepatitis B Core Antibodies Using Immunoglobulin G (IgG) ELISA Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.
Time Frame: Day 0 and Day 15 through Month 10 post-vaccination 1
|
Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA)
|
Day 0 and Day 15 through Month 10 post-vaccination 1
|
Number of Participants With Seropositivity to Hepatitis B Core Antigen Pre- and Post-Vaccination 1 With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.
Time Frame: Day 0 and Day 15 through Month 10 Post-vaccination 1
|
Seropositivity with ELISA was defined as a Pre- or post-vaccination antibody titer ≥ 100. Seropositivity with the Commercial Kit method was defined as a positive pre- or post-vaccination response. Seropositivity were assessed by means of enzyme linked immunosorbent assay (ELISA) and the Commercial Kit methods |
Day 0 and Day 15 through Month 10 Post-vaccination 1
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-261-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on Influenza A Vaccine: ACAM FLU-A
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedGlioma | Astrocytoma | OligodendrogliomaUnited States
-
Roswell Park Cancer InstituteCompletedAcute Myeloid Leukemia | Myelodysplastic SyndromeUnited States
-
University of RochesterNational Institutes of Health (NIH)Withdrawn2009 H1N1 InfluenzaUnited States
-
Emory UniversityNational Cancer Institute (NCI); Sanofi; National Institutes of Health (NIH)CompletedPlasma Cell NeoplasmUnited States
-
Masonic Cancer Center, University of MinnesotaTerminatedHematologic Malignancy | Hematopoietic Stem Cell TransplantUnited States
-
University of RochesterCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
PepTcell LimitedCompleted
-
University of Southern CaliforniaWithdrawnImmunosenescence